LLY
LLY's valuation is historically cheap, fundamentals are above averages and forward estimates point to improving growth and profitability.
LLY vs Historical averages
| Metric | Current | AverageAverage | Relative |
|---|---|---|---|
| PE | 37x | 57x | 35% lower-35% |
| PE percentile | 30 | 50 | 40% lower-40% |
| EPS | $29.80 | $9.50 | 214% higher+214% |
| FCF | $20.1B | $3.2B | 525% higher+525% |
| Loading historical comparisons… | |||
LLY’s earnings and cash flow are above their historical averages, while its earnings multiple is lower.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Forward valuation | Strongly improving |
| Forward earnings | Strong growth |
| Forward revenue | Growth |
| Forward profitability | Expanding |
| Analyst coverage | Moderate |
| Estimate dispersion | Moderate |
LLY’s outlook is generally improving, with growth expectations supporting the valuation case.
LLY PE Valuation
This table applies LLY's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.
LLY Earnings Per Share
This chart tracks LLY's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.
LLY Quarterly Revenue
This chart tracks LLY's quarterly revenue over time and shows how sales are changing from year to year.
LLY Free Cash Flow
This chart tracks LLY's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.
LLY Total Shares
This chart tracks changes in LLY's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.
LLY Net Leverage
Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.
LLY PE vs Healthcare Sector
This chart compares LLY's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.
LLY Weekly Price
This chart uses LLY's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.
LLY Weekly Moving Averages
This chart compares LLY's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.
LLY Yearly ROI
Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.
ZYME
ZYME's valuation appears fair, weak fundamentals weigh on the score, while forward estimates point to a return to profit and improving margins, though analyst coverage is limited and estimates vary widely.
ZYME vs Historical averages
| Metric | Current | AverageAverage | Relative |
|---|---|---|---|
| PE | 4x | 3.3x | 20% higher+20% |
| PE percentile | 82 | 49 | 67% higher+67% |
| EPS | -$2.02 | -$1.83 | $0.19 lower-$0.19 |
| FCF | -$120M | -$81.6M | -$38.4M-$38.4M |
| Loading historical comparisons… | |||
ZYME’s earnings are below their historical averages, while its earnings multiple is higher.
ZYME Forward outlook
| Metric | Outlook |
|---|---|
| Forward valuation | -- |
| Forward earnings | Turning positive |
| Forward revenue | Strong growth |
| Forward profitability | Strongly expanding |
| Analyst coverage | Limited |
| Estimate dispersion | Wide |
ZYME’s outlook is generally improving, supported by an expected return to profitability.
ZYME PE Valuation
This table applies ZYME's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.
ZYME Earnings Per Share
This chart tracks ZYME's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.
ZYME Quarterly Revenue
This chart tracks ZYME's quarterly revenue over time and shows how sales are changing from year to year.
ZYME Free Cash Flow
This chart tracks ZYME's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.
ZYME Total Shares
This chart tracks changes in ZYME's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.
ZYME Net Leverage
Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.
ZYME PE vs Healthcare Sector
This chart compares ZYME's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.
ZYME Weekly Price
This chart uses ZYME's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.
ZYME Weekly Moving Averages
This chart compares ZYME's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.
ZYME Yearly ROI
Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.